N-(2-bromobenzyl)-2,2-diethoxyacetamide | 608515-48-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-bromobenzyl)-2,2-diethoxyacetamide
• 英文别名: N-(2-bromo-benzyl)-2,2-diethoxy-acetamide；N-[(2-bromophenyl)methyl]-2,2-diethoxyacetamide
• CAS: 608515-48-6
• 化学式: C₁₃H₁₈BrNO₃
• 分子量: 316.195
• InChiKey: GKLPPPUNEANWGA-UHFFFAOYSA-N

物化性质

• 沸点：
  434.4±45.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-bromobenzyl)-2,2-diethoxyacetamide 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 tris-(dibenzylideneacetone)dipalladium(0) 吡啶 、 potassium fluoride 、 三叔丁基膦 、 硫酸 、 potassium iodide 、 锌 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 8,8-di-p-anisyl-3,3'-biisoquinoline
  参考文献：
  名称：

  Sterically non-hindering endocyclic ligands of the bi-isoquinoline family

  摘要：

  双异喹啉可用作制备新家族非空间位阻螯合物的结构单元，包括大环系统；八面体三螯合物铁(II)配合物的X射线结构证实了配体的内环性质，这表明这三种螯合物尽管呈新月形，但很容易容纳在金属的配位球中。

  DOI：

  10.1039/b513222c
• 作为产物：
  描述：

  邻溴苄胺 、 二乙氧基乙酸钠 在 吡啶 、 氯化亚砜 作用下， 以 乙醚 、 甲苯 为溶剂， 以60%的产率得到N-(2-bromobenzyl)-2,2-diethoxyacetamide
  参考文献：
  名称：

  Sterically non-hindering endocyclic ligands of the bi-isoquinoline family

  摘要：

  双异喹啉可用作制备新家族非空间位阻螯合物的结构单元，包括大环系统；八面体三螯合物铁(II)配合物的X射线结构证实了配体的内环性质，这表明这三种螯合物尽管呈新月形，但很容易容纳在金属的配位球中。

  DOI：

  10.1039/b513222c

文献信息

• [EN] BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE TYPE BICYCLYLARYL-ARYL-AMINE ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009103966A1

  公开（公告）日：2009-08-27

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation: (I).

  本发明一般涉及治疗化合物领域，更具体地涉及以下式（以下简称BCAA化合物）的某些双环芳基芳基胺化合物，该化合物在某些情况下抑制检查点激酶1（CHK1）激酶功能。本发明还涉及包含这种化合物的药物组合物，以及利用这种化合物和组合物在体内外抑制CHK1激酶功能，并用于治疗由CHK1介导的疾病和症状，通过抑制CHK1激酶功能得到缓解等，包括增殖性疾病如癌症等，可选地与另一药剂组合使用，例如，（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）微管靶向药物；和（e）电离辐射。
• Sterically non-hindering endocyclic ligands of the bi-isoquinoline family
  作者：Fabien Durola、Jean-Pierre Sauvage、Oliver S. Wenger

  DOI：10.1039/b513222c

  日期：——

  Bi-isoquinoline can be used as a building block to prepare a new family of non-sterically hindering chelates, including a macrocyclic system; the endocyclic nature of the ligands has been confirmed by the X-ray structure of an octahedral tris-chelate iron(II) complex, which shows that the three chelates are easily accommodated in the coordination sphere of the metal in spite of their crescent shape.

  双异喹啉可用作制备新家族非空间位阻螯合物的结构单元，包括大环系统；八面体三螯合物铁(II)配合物的X射线结构证实了配体的内环性质，这表明这三种螯合物尽管呈新月形，但很容易容纳在金属的配位球中。
• [EN] HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN<br/>[FR] DERIVES HETEROAROMATIQUES D'UREE EN TANT QUE MODULATEURS DU RECEPTEUR VR-1 POUR TRAITER LA DOULEUR
  申请人：MERCK SHARP & DOHME

  公开号：WO2003080578A1

  公开（公告）日：2003-10-02

  The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5 and R6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilising them.

  本发明提供了式（I）的化合物；其药学上可接受的盐和N-氧化物，其中A、B、D和E是C或N，但其中一个或多个是N，R1、R2、R3、R4、R5和R6是简单的取代基，n为0-3，y是芳基、杂环芳基、碳环芳基或融合碳环芳基基团；作为VR-1拮抗剂，用于治疗以疼痛和/或炎症为主的疾病或症状；其用于制造药物、包含它们的药物组合物以及利用它们的治疗方法。
• Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain
  申请人：Brown Elizabeth Rebecca

  公开号：US20050107388A1

  公开（公告）日：2005-05-19

  The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilising them.

  本发明提供了式（I）的化合物；其药学上可接受的盐和N-氧化物，其中A，B，D和E是C或N，但其中一个或多个是N，R1，R2，R3，R4，R5和R6是简单的取代基，n是0-3，y是芳基，杂环芳基，碳环芳基或融合的碳环芳基基团；作为VR-1拮抗剂，用于治疗疼痛和/或炎症占优势的疾病或症状；同样的用于制造药物、包含它们的制剂和利用它们的治疗方法。
• Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain
  申请人：——

  公开号：US07285563B2

  公开（公告）日：2007-10-23

  The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5 and R6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilizing them

  本发明提供了式(I)的化合物；其药学上可接受的盐和N-氧化物，其中A、B、D和E是C或N，但至少一个是N，R1、R2、R3、R4、R5和R6是简单的取代基，n为0-3，y是芳香基，杂环芳基，碳环基或融合碳环基；作为VR-1拮抗剂，用于治疗疼痛和/或炎症占优势的疾病或症状；将其用于制造药物，制备包含它们的制药组合物和利用它们的治疗方法。